We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
INCIDENCE OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER PATIENTS IN CLINICAL PRACTICE.
- Authors
MAZILU, LAURA; STĂNCULEANU, DANA-LUCIA; GHEORGHE, ANDREEA-DANIELA; VOINEA, FELIX; SUCEVEANU, ADRIAN-PAUL; PIȚURU, SILVIU; DIACONU, CAMELIA CRISTINA; PAREPA, IRINEL-RALUCA; STOIAN, ANCA PANTEA; POP, CORINA SILVIA; SUCEVEANU, ANDRA-IULIA
- Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is major neurologic toxic event, with a negative impact on patient's quality of life (QoL), and frequently requires dose modification or treatment discontinuation. The prevalence of CIPN is expecting to increase as cancer survival continue to improve. The study was conducted on 163 eligible patients with neurotoxic chemotherapy, from the Oncology Department of Clinical Emergency Hospital of Constanța, Romania between January 2017 and June 2018. Patients received a taxane - paclitaxel or docetaxel, platinum-based agents - cisplatin, carboplatin or oxaliplatin, either as single agent or combination. The incidence of CIPN was 68.09%. The highest incidence of CIPN was associated with paclitaxel (73.14%), and with oxaliplatin (72.22%), followed by cisplatin (30%), and with docetaxel (23.07%). Cumulative dose, regimen schedule, and treatment duration are important risk factors for the development of chemotherapy-induced peripheral neuropathy. Advanced age does not seem to be a significant risk factor of CIPN in our analysis in patients without significant comorbidity.
- Subjects
ROMANIA; PERIPHERAL neuropathy; CANCER patients; THERAPEUTICS; HOSPITAL emergency services; DISEASE risk factors
- Publication
Farmacia, 2019, Vol 67, Issue 3, p472
- ISSN
0014-8237
- Publication type
Article
- DOI
10.31925/farmacia.2019.3.14